Nesfatin-1

Nesfatin-1 is the clearest case in this batch of a compound sold ahead of its evidence, because there is no human interventional evidence of any kind.

It is an 82 residue cleavage product of nucleobindin-2, annotated in UniProt P80303 at residues 25 to 106. In rodents, central administration inhibits food intake, and it does so independently of leptin, which is why it attracted attention. That anorexigenic effect in rodents is real, replicated, and reviewed.

Two facts sit against any consumer framing.

The receptor has not been definitively identified. That is not a technical footnote. Without a known receptor there is no pharmacology to design against, no way to establish selectivity, no way to predict off-target effects, and no way to develop a small molecule at the target. A satiety peptide whose receptor is unknown is a research question, not a mechanism.

And nobody has given it to a person. Every human record located is observational, measuring circulating nesfatin-1 as a biomarker in knee osteoarthritis, endometrioma, polycystic ovary syndrome, type 2 diabetes and obesity, cord blood in intrauterine growth restriction, and weight regain after weight loss. A randomised trial that measured nesfatin-1 was a Nigella sativa trial in Hashimoto's thyroiditis, where nesfatin-1 was an outcome and the intervention was something else entirely.

Even as a biomarker it performs poorly. A systematic review and meta-analysis of blood nesfatin-1 in polycystic ovary syndrome found no significant difference between patients and controls, with a standardised mean difference of 0.03, a confidence interval of -0.71 to 0.77, and heterogeneity of 97.1%. That heterogeneity figure is itself informative: studies of this analyte disagree with each other profoundly.

Nesfatin-1 has no human interventional evidence, so there is no human evidence section on this page. That absence is the most important fact about it and it is stated here rather than implied by omission.

What exists is a rodent literature in which central administration reduces food intake, and a human literature in which circulating levels are measured in various patient groups and correlated with various things. Neither supports taking it.

The correlation literature is weaker than it looks. When the polycystic ovary syndrome studies were pooled in a systematic review and meta-analysis, the difference between patients and controls was a standardised mean difference of 0.03 with a confidence interval spanning zero in both directions, and heterogeneity of 97.1%. A body of studies that disagree with each other that comprehensively is describing measurement variability at least as much as biology, and assays for this peptide are known to differ.

The receptor point is worth restating because it is easy to skip past. Nobody has definitively identified what nesfatin-1 binds. Every satiety claim about it therefore rests on an observed effect with no identified receiver. That is a legitimate and interesting research position and it is an impossible basis for a product.

On funding: nesfatin-1 is an endogenous peptide fragment with no ownable composition, so no company has a reason to run the trial that would answer any of this. The thin record here is an economic fact as much as a scientific one. It is still a thin record, and it is still true that no human being has been given this peptide in a published study.

A cognitive endpoint is a measured one: a validated test of working memory, processing speed, attention, executive function or episodic recall, administered before and after, against a control group who did not know which arm they were in. None of the compounds in this batch has ever been tested that way. Rating scales of fatigue, global clinical impression, anxiety or hyperphagia are not cognitive endpoints, and neither is a hormone level. This matters because the marketing for several of these compounds describes focus, clarity and mental energy, and the underlying studies measured none of those things.